Basic Stats
| LEI | 54930036WK3GMCN17Z57 |
| CIK | 1015820 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Qiagen N.V.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| September 2, 2025 |
QIAGEN N.V. launches non-US offering of net share settled convertible bonds Exhibit 99.1 Media Release NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. QIAGEN N.V. launches non-US offering of net sha |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended August 31, 2025 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands (Address of principal exec |
|
| September 2, 2025 |
QIAGEN N.V. announces successful placement of new net share settled convertible bonds Exhibit 99.2 Media Release NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. QIAGEN N.V. announces successful placement of n |
|
| August 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands (Address of principal execut |
|
| August 21, 2025 |
Exhibit 99.1 QIAGEN N.V. and Subsidiaries U.S. GAAP Quarterly Report for the Period Ended June 30, 2025 Table of Contents Condensed Consolidated Financial Statements 2 Condensed Consolidated Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024 4 Condensed Consolidated Statements of Income (Loss) (unaudited) for the three and six months ended June 30, 2025 and 2024 5 Condensed Conso |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands (Address of principal execut |
|
| August 7, 2025 |
QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability Exhibit 99.1 Media Release QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability •Q2 2025 results: Net sales of $534 million (+7% actual rates); adjusted diluted EPS of $0.60 ◦Net sales +6% CER (constant exchange rates) above outlook for at least +5% CER and adjusted diluted EPS of $0.62 CER above outlook for at least $0.60 CER ◦29.9% adj. operating income margin up 1.5 p |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual reports under cover of |
|
| June 30, 2025 |
QIAGEN announces election of Stephen Rusckowski as Chairman of Supervisory Board Exhibit 99.1 QIAGEN announces election of Stephen Rusckowski as Chairman of Supervisory Board •Stephen H. Rusckowski elected as Chairman of the Supervisory Board after AGM; former Chairman Lawrence A. Rosen did not stand for re-election following 12 years of service •Shareholders approve all resolutions at AGM – including first-ever annual cash dividend and a synthetic share repurchase authorizati |
|
| June 2, 2025 |
QIAGEN N.V. Conflict Minerals Report For The Reporting Period January 1, 2024 to December 31, 2024 Exhibit 1.01 QIAGEN N.V. Conflict Minerals Report For The Reporting Period January 1, 2024 to December 31, 2024 Introduction This Conflict Minerals Report ("Report") for QIAGEN N.V. ("QIAGEN," the “Company,” or "we" or "us") has been prepared pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (“Rule 13p-1”), for the reporting period from January 1, 2024 to December 31, 20 |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Commission File Number 001-38332 QIAGEN N.V. (Exact name of Registrant as specified in its charter) n/a (Translation of Registrant’s name in English) The Netherlands (Jurisdiction of incorporation or organization) Hulsterweg 82 5912 PL Venlo The Netherlands 011-31-77-355-6600 (Address of p |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands (Address of principal execu |
|
| May 13, 2025 |
Exhibit 99.1 QIAGEN N.V. and Subsidiaries U.S. GAAP Quarterly Report for the Period Ended March 31, 2025 Table of Contents Condensed Consolidated Financial Statements 2 Condensed Consolidated Balance Sheets as of March 31, 2025 (unaudited) and December 31, 2024 4 Condensed Consolidated Statements of Income (unaudited) for the three months ended March 31, 2025 and 2024 5 Condensed Consolidated Stat |
|
| May 9, 2025 |
Exhibit 99.1 Media Release QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase •Q1 2025 results confirm preliminary announcement: Net sales of $483 million (+5% actual rates, +7% constant exchange rates, CER); adjusted diluted EPS of $0.55 ◦Net sales growth of +7% CER ahead of outlook for about +3% CER growth and |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands (Address of principal execu |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual reports under cover o |
|
| April 9, 2025 |
Exhibit 99.1 QIAGEN delivers strong preliminary Q1 2025 results exceeding outlook and raises full-year 2025 adjusted EPS outlook •Q1 2025 preliminary net sales rise 7% CER and adjusted diluted EPS results of at least $0.55 CER both above outlook despite challenging macro environment •Full-year 2025 adjusted diluted EPS outlook raised to about $2.35 CER (prior outlook about $2.28 CER) •On track to |
|
| March 31, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statement (No. 333-162052) on Form F-3 and the registration statements (Nos. 333-279834, 333-178035, 333-127393, 333-145171, 333-203220, and 333-217742) on Form S-8 of our reports dated March 28, 2025, with respect to the consolidated financial statements of QIAGEN |
|
| March 31, 2025 |
Exhibit 15.3 March 28, 2025 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We are currently principal accountants for QIAGEN N.V. (the “Company”) and, under the date of March 28, 2025, we reported on the consolidated financial statements of QIAGEN N.V. as of and for the years ended December 31, 2024 and 2023, and the effectiveness of internal control over financial |
|
| March 31, 2025 |
ARTICLES OF ASSOCIATION QIAGEN N.V. with seat in Venlo dated 28 January 2025 Exhibit 1.1 The undersigned: Casper Robert Nagtegaal, candidate civil law notary, acting as deputy of the vacant office of Professor Martin van Olffen, at the time civil law notary Amsterdam, declares with respect to the articles of association (the "Articles of Association") of the public limited liability company: QIAGEN N.V., with seat in Venlo, the Netherlands (the "Company") as follows: (i) t |
|
| March 31, 2025 |
CERTIFICATIONS UNDER SECTION 906 Exhibit 13.1 CERTIFICATIONS UNDER SECTION 906 Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of QIAGEN N.V., does hereby certify, to such officer’s knowledge, that: The Annual Report for the year ended December 31, 2024 (the “Form 20-F”) of the Company fully complies w |
|
| March 31, 2025 |
Exhibit 2.8 QIAGEN N.V. as Issuer and DEUTSCHE BANK AKTIENGESELLSCHAFT as Principal Paying Agent, Principal Conversion Agent and Issuing Agent and CONV-EX ADVISORS LIMITED as Calculation Agent AGENCY AGREEMENT relating to the USD 500 million Convertible Bonds due 2031 ISIN DE000A3L06J9 convertible into ordinary registered shares of QIAGEN N.V. Table of Contents 1Definitions and Interpretation..... |
|
| March 31, 2025 |
Exhibit 2.7 Global Bond THIS GLOBAL BOND AND THE SHARES TO BE DELIVERED UPON THE CONVERSION OF THE BONDS HAVE NOT AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). NEITHER THIS GLOBAL BOND NOR ANY PORTION HEREOF MAY BE OFFERED OR SOLD WITHIN THE UNITED STATES OF AMERICA OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS UNLESS AN EXEMP |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| March 31, 2025 |
CERTIFICATION UNDER SECTION 302 Exhibit 12.2 CERTIFICATION UNDER SECTION 302 I, Roland Sackers, certify that: 1.I have reviewed this annual report on Form 20-F of QIAGEN N.V; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with re |
|
| March 31, 2025 |
Exhibit 2.9 EXECUTION VERSION QIAGEN N.V. as Issuer and BOFA SECURITIES EUROPE SA and GOLDMAN SACHS BANK EUROPE SE and DEUTSCHE BANK AKTIENGESELLSCHAFT as Joint Global Coordinators and Joint Bookrunners and BNP PARIBAS and CITIGROUP GLOBAL MARKETS EUROPE AG and J.P. MORGAN SE as Joint Bookrunners SUBSCRIPTION AGREEMENT relating to the QIAGEN N.V. up to USD 500 million Convertible Bonds due 2031 IS |
|
| March 31, 2025 |
CERTIFICATION UNDER SECTION 302 Exhibit 12.1 CERTIFICATION UNDER SECTION 302 I, Thierry Bernard, certify that: 1.I have reviewed this annual report on Form 20-F of QIAGEN N.V; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with r |
|
| February 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2024 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands (Address of principal ex |
|
| February 7, 2025 |
QIAGEN delivers solid Q4 2024 growth ahead of outlook Exhibit 99.1 Media Release QIAGEN delivers solid Q4 2024 growth ahead of outlook •Q4 2024: Net sales of $521 million (+2% actual rates, +4% constant exchange rates (CER) core growth); diluted EPS of $0.39 and adjusted diluted EPS of $0.61 ◦Net sales of $525 million CER ahead of outlook for at least $520 million CER and adjusted diluted EPS of $0.61 CER ahead of outlook for at least $0.60 CER ◦QIAs |
|
| February 6, 2025 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Qiagen N.V. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the |
|
| January 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual reports under cover |
|
| January 16, 2025 |
Exhibit 99.1 QIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 million •Capital return to be conducted through synthetic share repurchase – combines a fast direct capital repayment to shareholders with a reverse stock split that enhances EPS •Return of approximately $300 million – maximum approved by shareholders – set to be completed in late January |
|
| January 13, 2025 |
QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase Exhibit 99.1 QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase •Capital return to be conducted through synthetic share repurchase – combines a fast direct capital repayment to shareholders with a reverse stock split that enhances EPS •Return of up to $300 million – maximum approved by shareholders – set to be completed in late January 2025 •Builds on |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual reports under cover |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands (Address of principal e |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands (Address of principal e |
|
| November 8, 2024 |
QGEN / Qiagen N.V. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Qiagen N.V. (Name of Issuer) Common Stock (Title of Class of Securities) N72482149 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| November 8, 2024 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Qiagen N.V. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands (Address of principal executive office) Ind |
|
| November 8, 2024 |
Exhibit 99.1 QIAGEN N.V. and Subsidiaries U.S. GAAP Quarterly Report for the Period Ended September 30, 2024 Table of Contents Condensed Consolidated Financial Statements 2 Condensed Consolidated Balance Sheets as of September 30, 2024 (unaudited) and December 31, 2023 4 Condensed Consolidated Statements of Income (Loss) (unaudited) for the three and nine months ended September 30, 2024 and 2023 5 |
|
| November 8, 2024 |
QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook Exhibit 99.1 Media Release QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook •Q3 2024: Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER); diluted EPS of $0.44 and adjusted diluted EPS of $0.57 ◦Net sales of $502 million CER ahead of outlook for at least $495 million CER and adjusted diluted EPS of $0.58 CER ahead of ou |
|
| September 4, 2024 |
QIAGEN N.V. announces conversion price of new net share settled convertible bonds Exhibit 99.1 Media Release NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. QIAGEN N.V. announces conversion price of new n |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual reports under cover |
|
| September 3, 2024 |
QIAGEN N.V. launches non-US offering of net share settled convertible bonds Exhibit 99.1 Media Release NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. QIAGEN N.V. launches non-US offering of net sha |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual reports under cover |
|
| August 2, 2024 |
Exhibit 99.5 |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands (Address of principal execut |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands (Address of principal execut |
|
| August 2, 2024 |
Exhibit 99.7Table of Contents Overview 3 Common Shares Management Report 9 Business and Operating Environment 22 Operating and Financial Review 31 Risks and Risk Management 50 Quantitative and Qualitative Disclosures about Market Risk 54 Sustainability Statement 115 Outlook Corporate Governance 116 Message from the Chair of the Supervisory Board 118 Governance Structure 120 Managing Board 121 Supe |
|
| August 2, 2024 |
QIAGEN delivers solid performance and exceeds outlook for Q2 2024 Exhibit 99.1 Media Release QIAGEN delivers solid performance and exceeds outlook for Q2 2024 •Q2 2024: Net sales of $496 million (+0% actual rates, +1% constant exchange rates, CER); net loss per share of $0.83 but adjusted diluted EPS of $0.55 ◦Net sales at CER of $502 million ahead of outlook for at least $495 million CER and adjusted diluted EPS of $0.55 CER ahead of $0.52 CER outlook ◦28.4% ad |
|
| August 2, 2024 |
Exhibit 99.7 Table of Contents Overview 3 Common Shares Management Report 9 Business and Operating Environment 22 Operating and Financial Review 31 Risks and Risk Management 50 Quantitative and Qualitative Disclosures about Market Risk 54 Sustainability Statement 115 Outlook Corporate Governance 116 Message from the Chair of the Supervisory Board 118 Governance Structure 120 Managing Board 121 Sup |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 30, 2024 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual reports under cover o |
|
| August 2, 2024 |
Exhibit 99.6 2024 Voting Results Voting Results of the Annual General Meeting of Shareholders of QIAGEN N.V. QIAGEN's Annual General Meeting of Shareholders (the "Annual Meeting") was held on June 21, 2024. The following actions were taken at the Annual Meeting: 1.Opening (no voting item) 2.Managing Board Report for the year ended December 31, 2023 (“Calendar Year 2023”) (no voting item) 3.Complia |
|
| August 2, 2024 |
NOTICE OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 NOTICE OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of Shareholders (the "Annual General Meeting") of QIAGEN N.V., a public limited liability company organized and existing under the laws of the Netherlands, with corporate seat in Venlo, the Netherlands (the "Company" or "QIAGEN") will be held on Friday, June 21, 2024 at 10:00, l |
|
| August 2, 2024 |
Exhibit 99.1 QIAGEN N.V. and Subsidiaries U.S. GAAP Quarterly Report for the Period Ended June 30, 2024 Table of Contents Condensed Consolidated Financial Statements 2 Condensed Consolidated Balance Sheets as of June 30, 2024 (unaudited) and December 31, 2023 4 Condensed Consolidated Statements of (Loss) Income (unaudited) for the three and six months ended June 30, 2024 and 2023 5 Condensed Conso |
|
| August 2, 2024 |
BENEFICIAL SHAREHOLDER ATTENDANCE FORM Exhibit 99.3 BENEFICIAL SHAREHOLDER ATTENDANCE FORM TO: QIAGEN N.V. c/o Equiniti Trust Company, LLC Attention: Proxy Department 48 Wall Street, Floor 23 New York, NY 10005 QIAGEN N.V. Annual General Meeting of Shareholders June 21, 2024 The undersigned, beneficial holder of registered shares of QIAGEN N.V. (the "Company"), hereby notifies the Company that he/she/it wishes to attend and to exercise |
|
| August 2, 2024 |
REGISTERED SHAREHOLDER ATTENDANCE FORM Exhibit 99.4 REGISTERED SHAREHOLDER ATTENDANCE FORM TO: QIAGEN N.V. c/o Equiniti Trust Company, LLC Attention: Proxy Department 48 Wall Street, Floor 23 New York, NY 10005 QIAGEN N.V. Annual General Meeting of Shareholders June 21, 2024 The undersigned, holder of registered shares of QIAGEN N.V. (the "Company"), hereby notifies the Company that he/she/it wishes to attend and to exercise his/her/it |
|
| August 2, 2024 |
Exhibit 99.2 Dear Shareholder: You are cordially invited to attend the Annual General Meeting of Shareholders of QIAGEN N.V. (the “Company”) to be held on Friday, June 21, 2024 at 10:00, local time, at Maaspoort, Oude Markt 30, 5911 HH Venlo, The Netherlands. We have attached a Notice of Annual General Meeting, including the Agenda and Explanatory Notes thereto, and enclosed an attendance form and |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 30, 2024 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual reports under cover o |
|
| June 24, 2024 |
COMMITTED TO SOLID PROFITABLE GROWTH Capital Markets Day June 17, 20242 June 17, 2024 Capital Markets Day 2024 Photos and video recordings of participants will be taken during this event. |
|
| June 24, 2024 |
QIAGEN announces 2028 strategy for solid profitable growth Exhibit 99.1 QIAGEN announces 2028 strategy for solid profitable growth •Hosts Capital Markets Day event in New York to outline strategy anchored by sharpened focus on growth pillars set to drive about 7% CER sales CAGR from 2024-2028 •Targeting at least 31% CER adjusted operating income margin in 2028 from portfolio streamlining (including NeuMoDx decision), operational efficiency gains and digit |
|
| June 24, 2024 |
COMMITTED TO SOLID PROFITABLE GROWTH Capital Markets Day June 17, 2024 2June 17, 2024 Capital Markets Day 2024 Photos and video recordings of participants will be taken during this event. |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 30, 2024 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual reports under cover o |
|
| June 6, 2024 |
Exhibit 99.1 QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition period •NeuMoDx 96 and NeuMoDx 288 Molecular Systems decision taken in light of challenging post-pandemic market development trends •Reaffirms Q2 2024 outlook, raises full-year 2024 outlook for adjusted diluted EPS to $2.14 CER, has started discussions with NeuMoDx customers to assess impa |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Commission File Number 001-38332 QIAGEN N.V. (Exact name of Registrant as specified in its charter) n/a (Translation of Registrant’s name in English) The Netherlands (Jurisdiction of incorporation or organization) Hulsterweg 82 5912 PL Venlo The Netherlands 011-31-77-355-6600 (Address of p |
|
| May 31, 2024 |
QIAGEN N.V. Conflict Minerals Report For The Reporting Period January 1, 2023 to December 31, 2023 Exhibit 1.01 QIAGEN N.V. Conflict Minerals Report For The Reporting Period January 1, 2023 to December 31, 2023 Introduction This Conflict Minerals Report ("Report") for QIAGEN N.V. ("QIAGEN," the “Company,” or "we" or "us") has been prepared pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (“Rule 13p-1”), for the reporting period from January 1, 2023 to December 31, 20 |
|
| May 30, 2024 |
Exhibit 99.1 QIAGEN N.V. 2023 STOCK PLAN 1.DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this QIAGEN N.V. 2023 Stock Plan, have the following meanings: “Administrator” means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case the term “Administrator” means the Committee. “Affi |
|
| May 30, 2024 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) QIAGEN N.V. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common shares, par valu |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QIAGEN N.V. (Exact name of Registrant as specified in its charter) The Netherlands 98-0391359 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Hulsterweg 82 5912 PL Venlo The Netherlands +011-31-77-355-6600 (Addr |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands (Address of principal execu |
|
| May 1, 2024 |
Exhibit 99.1 QIAGEN N.V. and Subsidiaries U.S. GAAP Quarterly Report for the Period Ended March 31, 2024 Table of Contents Condensed Consolidated Financial Statements 2 Condensed Consolidated Balance Sheets as of March 31, 2024 (unaudited) and December 31, 2023 4 Condensed Consolidated Statements of Income (unaudited) for the three months ended March 31, 2024 and 2023 5 Condensed Consolidated Stat |
|
| May 1, 2024 |
QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance Exhibit 99.1 Media Release QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance •Q1 2024: Net sales of $459 million (-5% actual rates, -5% constant exchange rates, CER); diluted EPS of $0.36 and adjusted diluted EPS of $0.46 ◦Net sales at CER of $462 million ahead of outlook for at least $455 million CER and adj. diluted EPS of $0.47 CER ahead of $0.44 C |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands (Address of principal execu |
|
| March 11, 2024 |
Exhibit 97.1 QIAGEN N.V. CLAWBACK POLICY I.Introduction The Management Board and Supervisory Board of QIAGEN N.V: (the “Company”) believe that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Management Board and Supervisory |
|
| March 11, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statement (No. 333-162052) on Form F-3 and the registration statements (Nos. 333-178035, 333-127393, 333-145171, 333-203220, and 333-217742) on Form S-8 of our reports dated March 8, 2024, with respect to the consolidated financial statements of QIAGEN N.V. and the |
|
| March 11, 2024 |
Exhibit 4.3 QIAGEN N.V. 2023 STOCK PLAN 1.DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this QIAGEN N.V. 2023 Stock Plan, have the following meanings: “Administrator” means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case the term “Administrator” means the Committee. “Affil |
|
| March 11, 2024 |
CERTIFICATIONS UNDER SECTION 906 Exhibit 13.1 CERTIFICATIONS UNDER SECTION 906 Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of QIAGEN N.V., does hereby certify, to such officer’s knowledge, that: The Annual Report for the year ended December 31, 2023 (the “Form 20-F”) of the Company fully complies w |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| March 11, 2024 |
ARTICLES OF ASSOCIATION QIAGEN N.V. with seat in Venlo dated 29 January 2024 Exhibit 1.1 The undersigned: Casper Robert Nagtegaal, candidate civil law notary, acting for Professor Martin van Olffen, civil law notary Amsterdam, declares with respect to the articles of association (the "Articles of Association") of the public limited liability company: QIAGEN N.V., with seat in Venlo, the Netherlands (the "Company") as follows: (i) the Articles of Association correspond with |
|
| March 11, 2024 |
CERTIFICATION UNDER SECTION 302 Exhibit 12.2 CERTIFICATION UNDER SECTION 302 I, Roland Sackers, certify that: 1.I have reviewed this annual report on Form 20-F of QIAGEN N.V; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with re |
|
| March 11, 2024 |
Insider Trading Policy Exhibit 11.1 Dealings in QIAGEN stock based on non-public material information about the Company are strictly prohibited under US and German Securities laws. These laws are complex and penalties can be severe. In order to protect QIAGEN and its employees from such sanctions, this policy explains the basic rules which apply to potential Insiders (individuals with knowledge of |
|
| March 11, 2024 |
CERTIFICATION UNDER SECTION 302 Exhibit 12.1 CERTIFICATION UNDER SECTION 302 I, Thierry Bernard, certify that: 1.I have reviewed this annual report on Form 20-F of QIAGEN N.V; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with r |
|
| February 9, 2024 |
QGEN / Qiagen N.V. / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6 )* QIAGEN N.V. (Name of Issuer) Common Stock (Title of Class of Securities) N72482123 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2023 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark w |
|
| January 23, 2024 |
Exhibit 99.1 QIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 million Venlo, the Netherlands, January 18, 2024 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of the synthetic share repurchase plan to return up to approximately $300 million that combines a direct capital repayment to QIAGEN shareholde |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 31, 2024 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual reports under cove |
|
| January 8, 2024 |
QIAGEN announces plans to return approximately $300 million to shareholders QIAGEN announces plans to return approximately $300 million to shareholders •Capital return to be conducted through synthetic share repurchase •Return of up to $300 million – maximum approved by shareholders in 2023 – designed to enable efficient return of cash to shareholders and enhance EPS •Implementation planned to be completed in late January 2024 Venlo, the Netherlands, January 7, 2024 – QIAGEN N. |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 31, 2024 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual reports under cove |
|
| December 6, 2023 |
QGEN / Qiagen NV / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* QIAGEN N.V. (Name of Issuer) Common Stock (Title of Class of Securities) N72482123 (CUSIP Number) November 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| November 1, 2023 |
NOTICE OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 NOTICE OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of Shareholders (the "Annual General Meeting") of QIAGEN N.V., a public limited liability company organized and existing under the laws of the Netherlands, with corporate seat in Venlo, the Netherlands (the "Company" or "QIAGEN") will be held on Thursday, June 22, 2023 at 10:00, |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registra |
|
| November 1, 2023 |
Exhibit 99.2 Dear Shareholder: You are cordially invited to attend the Annual General Meeting of Shareholders of QIAGEN N.V. (the “Company”) to be held on Thursday, June 22, 2023 at 10:00, local time, at Maaspoort, Oude Markt 30, 5911 HH Venlo, The Netherlands. We have attached a Notice of Annual General Meeting, including the Agenda and Explanatory Notes thereto, and enclosed an attendance form a |
|
| November 1, 2023 |
EX-99.7 8 exhibit9972022ifrsannualre.htm EX-99.7 Exhibit 99.7 QIAGEN N.V. TABLE OF CONTENTS Annual Report 2022 Page Supervisory Board Report 1 Management Report 12 Corporate Governance Report 65 Environmental, Social and Governance Report 80 Remuneration Report 113 Responsibility Statement of the Managing Board 134 Consolidated Financial Statements QIAGEN N.V. and Subsidiaries Consolidated Balance |
|
| November 1, 2023 |
BENEFICIAL SHAREHOLDER ATTENDANCE FORM Exhibit 99.3 BENEFICIAL SHAREHOLDER ATTENDANCE FORM TO: QIAGEN N.V. c/o American Stock Transfer and Trust Company Attention: Proxy Department 6201 15th Avenue Brooklyn, New York 11219 QIAGEN N.V. Annual General Meeting of Shareholders June 22, 2023 The undersigned, beneficial holder of registered shares of QIAGEN N.V. (the "Company"), hereby notifies the Company that he/she/it wishes to attend and |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual re |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark |
|
| November 1, 2023 |
REGISTERED SHAREHOLDER ATTENDANCE FORM Exhibit 99.4 REGISTERED SHAREHOLDER ATTENDANCE FORM TO: QIAGEN N.V. c/o American Stock Transfer and Trust Company Attention: Proxy Department 6201 15th Avenue Brooklyn, New York 11219 QIAGEN N.V. Annual General Meeting of Shareholders June 22, 2023 The undersigned, holder of registered shares of QIAGEN N.V. (the "Company"), hereby notifies the Company that he/she/it wishes to attend and to exercis |
|
| November 1, 2023 |
Exhibit 99.6 2023 Voting Results Voting Results of the Annual General Meeting of Shareholders of QIAGEN N.V. QIAGEN's Annual General Meeting of Shareholders (the "Annual Meeting") was held on June 22, 2023. The following actions were taken at the Annual Meeting: 1.Opening (no voting item) 2. Managing Board Report for the year ended December 31, 2022 (“Calendar Year 2022”) (no voting item) 3.Superv |
|
| November 1, 2023 |
Exhibit 99.5 |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual reports |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark wheth |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Commission File Number 001-38332 QIAGEN N.V. (Exact name of Registrant as specified in its charter) n/a (Translation of Registrant’s name in English) The Netherlands (Jurisdiction of incorporation or organization) Hulsterweg 82 5912 PL Venlo The Netherlands 011-31-77-355-6600 (Address of p |
|
| May 30, 2023 |
QIAGEN N.V. Conflict Minerals Report For The Reporting Period January 1, 2022 to December 31, 2022 EX-1.01 2 exhibit101conflictminerals.htm EX-1.01 Exhibit 1.01 QIAGEN N.V. Conflict Minerals Report For The Reporting Period January 1, 2022 to December 31, 2022 Introduction This Conflict Minerals Report ("Report") for QIAGEN N.V. ("QIAGEN," the “Company,” or "we" or "us") has been prepared pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (“Rule 13p-1”), for the reporti |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual report |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whet |
|
| March 13, 2023 |
Schuldscheindarlehensvertrag (der „Darlehensvertrag“) Exhibit 2.13 In accordance with Instruction 2 to Item 601 of Regulation S-K, below is a schedule setting forth details in which the omitted loan agreements differ from the form of loan agreement that follows: Currency Notional Amount Interest Rate Maturity EUR €51.5 million Floating 6M EURIBOR + 0.55% July 2025 EUR €62.0 million Fixed 2.741% July 2027 EUR €29.5 million Floating 6M EURIBOR + 0.70% |
|
| March 13, 2023 |
CERTIFICATION UNDER SECTION 302 Exhibit 12.1 CERTIFICATION UNDER SECTION 302 I, Thierry Bernard, certify that: 1.I have reviewed this annual report on Form 20-F of QIAGEN N.V; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with r |
|
| March 13, 2023 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statement (No. 333‑162052) on Form F-3 and the registration statements (Nos. 333-178035, 333-127393, 333-145171, 333-203220, and 333-217742) on Form S-8 of QIAGEN N.V. of our reports dated March 10, 2023, with respect to the consolidated financial statements of QIA |
|
| March 13, 2023 |
Exhibit 2.14 NAMENSSCHULDVERSCHREIBUNG / REGISTERED NOTE ausgegeben am 16. August 2022 und fällig am 16. August 2035 issued on 16 August 2022 and due on 16 August 2035 im Gesamtnennbetrag von with an aggregate nominal amount of EUR 70.000.000 (in Worten: siebzig Millionen Euro) EUR 70,000,000 (in words: seventy million Euro) Diese Urkunde (die „Urkunde”) verbrieft 70 Namensschuldverschreibungen im |
|
| March 13, 2023 |
CERTIFICATIONS UNDER SECTION 906 Exhibit 13.1 CERTIFICATIONS UNDER SECTION 906 Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of QIAGEN N.V., does hereby certify, to such officer’s knowledge, that: The Annual Report for the year ended December 31, 2022 (the “Form 20-F”) of the Company fully complies w |
|
| March 13, 2023 |
CERTIFICATION UNDER SECTION 302 Exhibit 12.2 CERTIFICATION UNDER SECTION 302 I, Roland Sackers, certify that: 1.I have reviewed this annual report on Form 20-F of QIAGEN N.V; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with re |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2022 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark w |
|
| February 8, 2023 |
QGEN / QIAGEN N.V. / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* QIAGEN N.V. (Name of Issuer) Common Stock (Title of Class of Securities) N72482123 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| November 9, 2022 |
6-K 1 a2022agm6-k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2022 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by chec |
|
| November 9, 2022 |
6-K 1 a2022q3pr6-k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherla |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual re |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual reports |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant?s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark wheth |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Commission File Number 001-38332 QIAGEN N.V. (Exact name of Registrant as specified in its charter) n/a (Translation of Registrant?s name in English) The Netherlands (Jurisdiction of incorporation or organization) Hulsterweg 82 5912 PL Venlo The Netherlands 011-31-77-355-6600 (Address of p |
|
| June 1, 2022 |
QIAGEN N.V. Conflict Minerals Report For The Reporting Period January 1, 2021 to December 31, 2021 EX-1.01 2 exhibit101conflictminerals.htm EX-1.01 CONFLICT MINERALS REPORT Exhibit 1.01 QIAGEN N.V. Conflict Minerals Report For The Reporting Period January 1, 2021 to December 31, 2021 Introduction This Conflict Minerals Report ("Report") for QIAGEN N.V. ("QIAGEN," the “Company,” or "we" or "us") has been prepared pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (“Rule |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual report |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant?s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whet |
|
| March 14, 2022 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statement (No. 333‑162052) on Form F-3 and the registration statements (Nos. 333-178035, 333-127393, 333-145171, 333-203220, and 333-217742) on Form S-8 of QIAGEN N.V. of our reports dated March 14, 2022, with respect to the consolidated financial statements of QIA |
|
| March 14, 2022 |
CERTIFICATION UNDER SECTION 302 Exhibit 12.1 CERTIFICATION UNDER SECTION 302 I, Thierry Bernard, certify that: 1.I have reviewed this annual report on Form 20-F of QIAGEN N.V; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with r |
|
| March 14, 2022 |
CERTIFICATIONS UNDER SECTION 906 Exhibit 13.1 CERTIFICATIONS UNDER SECTION 906 Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of QIAGEN N.V., does hereby certify, to such officer’s knowledge, that: The Annual Report for the year ended December 31, 2021 (the “Form 20-F”) of the Company fully complies w |
|
| March 14, 2022 |
CERTIFICATION UNDER SECTION 302 Exhibit 12.2 CERTIFICATION UNDER SECTION 302 I, Roland Sackers, certify that: 1.I have reviewed this annual report on Form 20-F of QIAGEN N.V; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with re |
|
| March 14, 2022 |
EX-1.1 2 exhibit11articlesofassocia.htm EX-1.1 Exhibit 1.1 The undersigned: Professor Martin van Olffen, civil law notary in Amsterdam, declares with respect to the articles of association (the "Articles of Association") of the public limited liability company: QIAGEN N.V., with seat in Venlo, the Netherlands (the "Company") as follows: (i) the Articles of Association correspond with the document |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| February 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2021 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant?s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark w |
|
| February 2, 2022 |
QGEN / QIAGEN N.V. / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* QIAGEN N.V. (Name of Issuer) Common Stock (Title of Class of Securities) N72482123 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant?s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual re |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month ended June 30, 2021 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant?s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the regi |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant?s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark wheth |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual reports |
|
| July 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant?s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark wheth |
|
| May 5, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2021 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant?s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whet |
|
| May 5, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual report |
|
| March 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Commission File Number 001-38332 QIAGEN N.V. (Exact name of Registrant as specified in its charter) n/a (Translation of Registrant?s name in English) The Netherlands (Jurisdiction of incorporation or organization) Hulsterweg 82 5912 PL Venlo The Netherlands 011-31-77-355-6600 (Address of p |
|
| March 5, 2021 |
Exhibit 2.12 THIS GLOBAL BOND AND THE SHARES TO BE DELIVERED UPON THE CONVERSION OF THE BONDS HAVE NOT AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). NEITHER THIS GLOBAL BOND NOR ANY PORTION HEREOF MAY BE OFFERED OR SOLD WITHIN THE UNITED STATES OF AMERICA OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS UNLESS AN EXEMPTION FROM T |
|
| March 5, 2021 |
CERTIFICATION UNDER SECTION 302 Exhibit 12.1 CERTIFICATION UNDER SECTION 302 I, Thierry Bernard, certify that: 1.I have reviewed this annual report on Form 20-F of QIAGEN N.V; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with r |
|
| March 5, 2021 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm The Supervisory Board QIAGEN N.V.: We consent to the incorporation by reference in the registration statement (No. 333?162052) on Form F-3 and the registration statements (Nos. 333-178035, 333-127393, 333-145171, 333-203220, and 333-217742) on Form S-8 of QIAGEN N.V. of our reports dated March 4, 2021, with respect to the consol |
|
| March 5, 2021 |
Exhibit 2.14 EXECUTION VERSION Dated 10 December 2020 QIAGEN N.V. as Issuer and DEUTSCHE BANK AKTIENGESELLSCHAFT and GOLDMAN SACHS INTERNATIONAL and MERRILL LYNCH INTERNATIONAL as Joint Global Coordinators and Joint Bookrunners and BNP PARIBAS and HSBC TRINKAUS & BURKHARDT AG and UNICREDIT BANK AG as Joint Bookrunners SUBSCRIPTION AGREEMENT relating to the QIAGEN N.V. up to USD 500,000,000 Convert |
|
| March 5, 2021 |
CERTIFICATIONS UNDER SECTION 906 Exhibit 13.1 CERTIFICATIONS UNDER SECTION 906 Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of QIAGEN N.V., does hereby certify, to such officer?s knowledge, that: The Annual Report for the year ended December 31, 2020 (the ?Form 20-F?) of the Company fully complies w |
|
| March 5, 2021 |
[Agreed form Linklaters Dutch law opinion] Exhibit 2.13 EXECUTION VERSION PURCHASE AGENT AGREEMENT 10 December 2020 Deutsche Bank Aktiengesellschaft Mainzer Landstra?e 11-17 60329 Frankfurt am Main Germany Goldman Sachs International Plumtree Court 25 Shoe Lane London EC4A 4AU United Kingdom Merrill Lynch International 2 King Edward Street London EC1A 1HQ United Kingdom BNP PARIBAS 16, boulevard des Italiens 75009 Paris France HSBC Trinkau |
|
| March 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| March 5, 2021 |
CERTIFICATION UNDER SECTION 302 Exhibit 12.2 CERTIFICATION UNDER SECTION 302 I, Roland Sackers, certify that: 1.I have reviewed this annual report on Form 20-F of QIAGEN N.V; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with re |
|
| February 24, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the monthly period ended February 28, 2021 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant?s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whe |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* QIAGEN N.V. (Name of Issuer) Common Stock (Title of Class of Securities) N72482123 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 10, 2021 |
Current Report of Foreign Issuer - 6-K 6-K 1 a2020q4pr6-k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2020 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlan |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Qiagen NV (Name of Issuer) Common Stock (Title of Class of Securities) N72482123 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 22, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* QIAGEN N.V. (Name of Issuer) Ordinary Shares, par value €0.01 per share (Title of Class of Securities) N72482123 (CUSIP Number) Shulamit Leviant, Esq. c/o Davidson Kempner Capital Management LP 520 Madison Avenue, 30th Floor New York, New York 10022 (212) 446 4053 W |
|
| January 8, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the monthly period ended January 31, 2021 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whet |
|
| December 18, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the monthly period ended December 31, 2020 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whe |
|
| December 17, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the monthly period ended December 31, 2020 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whe |
|
| December 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the monthly period ended December 31, 2020 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant?s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whe |
|
| December 8, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the monthly period ended December 31, 2020 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whe |
|
| November 12, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the monthly period ended November 30, 2020 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whe |
|
| November 2, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual re |
|
| October 27, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark |
|
| October 13, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark |
|
| August 21, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the monthly period ended August 31, 2020 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark wheth |
|
| August 13, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the monthly period ended August 31, 2020 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark wheth |
|
| August 13, 2020 |
SC TO-T/A 1 tm2016683-30sctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 24) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror |
|
| August 13, 2020 |
Press Release, dated August 13, 2020. Exhibit (a)(5)(FF) News Media Contact Information: Karen Kirkwood Phone: 617-835-1356 E-mail: karen. |
|
| August 13, 2020 |
Exhibit (a)(5)(EE) Quebec B.V. Breda, The Netherlands Notification pursuant to Section 23 para. 1 sentence 1 no. 2 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz — WpÜG) and regarding the non-fulfillment of an offer condition NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY OTHER JURISDICTION WHERE TO DO SO WOULD |
|
| August 13, 2020 |
EX-99.(a)(5)(V) Exhibit (a)(5)(V) QIAGEN to continue successful growth strategy focused on execution and greater value creation after voluntary public takeover offer falls short • Tender offer acceptance of 47% did not reach minimum threshold of 66.67% • QIAGEN Supervisory Board and Managing Board respect the views of shareholders • Focus on execution with strong outlook for 2020 and 2021, QIAGEN |
|
| August 13, 2020 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) QIAGEN N.V. (Name of Subject Company) QIAGEN N.V. (Name of Persons Filing Statement) Ordinary shares, par value EUR 0.01 per share (Title of Class of Securities) N7248212 |
|
| August 11, 2020 |
Press Release, dated August 11, 2020. Exhibit (a)(5)(DD) News Media Contact Information: Karen Kirkwood Investor Contact Information: Ken Apicerno Phone: 781-622-1306 Phone: 781-622-1294 E-mail: karen. |
|
| August 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 23) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying statu |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 22) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying statu |
|
| August 10, 2020 |
Exhibit (a)(5)(CC) Quebec B.V. Breda, The Netherlands Notification pursuant to Section 23 para. 1 sentence 1 no. 1 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz — WpÜG) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY OTHER JURISDICTION WHERE TO DO SO WOULD VIOLATE THE LAWS OF SUCH JURISDICTION. On May 18, 2020, |
|
| August 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 21) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying statu |
|
| August 7, 2020 |
Exhibit (a)(5)(BB) Quebec B.V. Breda, The Netherlands Notification pursuant to Section 23 para. 1 sentence 1 no. 1 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz — WpÜG) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY OTHER JURISDICTION WHERE TO DO SO WOULD VIOLATE THE LAWS OF SUCH JURISDICTION. On May 18, 2020, |
|
| August 6, 2020 |
Exhibit (a)(5)(AA) Quebec B.V. Breda, The Netherlands Notification pursuant to Section 23 para. 1 sentence 1 no. 1 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz — WpÜG) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY OTHER JURISDICTION WHERE TO DO SO WOULD VIOLATE THE LAWS OF SUCH JURISDICTION. On May 18, 2020, |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 20) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying sta |
|
| August 5, 2020 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) QIAGEN N.V. (Name of Subject Company) QIAGEN N.V. (Name of Persons Filing Statement) Ordinary shares, par value EUR 0.01 per share (Title of Class of Securities) N7248212 |
|
| August 5, 2020 |
Exhibit (a)(5)(Z) Quebec B.V. Breda, The Netherlands Notification pursuant to Section 23 para. 1 sentence 1 no. 1 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz — WpÜG) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY OTHER JURISDICTION WHERE TO DO SO WOULD VIOLATE THE LAWS OF SUCH JURISDICTION. On May 18, 2020, |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 18) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying sta |
|
| August 5, 2020 |
Exhibit (a)(5)(X) Quebec B.V. Breda, The Netherlands Notification pursuant to Section 23 para. 1 sentence 1 no. 1 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz — WpÜG) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY OTHER JURISDICTION WHERE TO DO SO WOULD VIOLATE THE LAWS OF SUCH JURISDICTION. On May 18, 2020, |
|
| August 5, 2020 |
QIAGEN reports full results for second quarter and first half of 2020 EX-99.(a)(5)(U) Exhibit (a)(5)(U) QIAGEN reports full results for second quarter and first half of 2020 • Q2 2020 results: • Net sales of $443.3 million (+16% actual, +19% CER) • Diluted EPS $0.38; adjusted EPS $0.55 ($0.56 CER, +70% CER) • H1 2020 results: • Net sales of $815.3 million (+12% actual, +14% CER) • Diluted EPS $0.56; adjusted EPS $0.89 ($0.90 CER, +50% CER) • QIAGEN Boards have reaff |
|
| August 5, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark wheth |
|
| August 5, 2020 |
- AMENDMENT NO 19 TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 19) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying sta |
|
| August 5, 2020 |
Press Release, dated August 4, 2020. Exhibit (a)(5)(Y) News Media Contact Information: Karen Kirkwood Phone: 781-622-1306 E-mail: karen. |
|
| August 5, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Commission File Number 001-38332 QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the registrant files or will file annual reports |
|
| August 4, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month ended June 30, 2020 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark whether the regi |
|
| August 3, 2020 |
QGEN / QIAGEN N.V. / DAVIDSON KEMPNER PARTNERS - QIAGEN N.V. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. [])* QIAGEN N.V. (Name of Issuer) Ordinary Shares, par value €0.01 per share (Title of Class of Securities) N72482123 (CUSIP Number) Shulamit Leviant, Esq. c/o Davidson Kempner Capital Management LP 520 Madison Avenue, 30th Floor New York, New York 10022 (212) 446 4053 Wi |
|
| August 3, 2020 |
Exhibit (a)(5)(W) Quebec B.V. Breda, The Netherlands Notification pursuant to Section 23 para. 1 sentence 1 no. 1 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz — WpÜG) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY OTHER JURISDICTION WHERE TO DO SO WOULD VIOLATE THE LAWS OF SUCH JURISDICTION. On May 18, 2020, |
|
| August 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 17) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying sta |
|
| July 27, 2020 |
Exhibit (a)(5)(V) Quebec B.V. Breda, The Netherlands Notification pursuant to Section 23 para. 1 sentence 1 no. 1 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz — WpÜG) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY OTHER JURISDICTION WHERE TO DO SO WOULD VIOLATE THE LAWS OF SUCH JURISDICTION. On May 18, 2020, |
|
| July 27, 2020 |
- AMENDMENT NO. 16 TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 16) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying sta |
|
| July 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 15) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying sta |
|
| July 23, 2020 |
Excerpt from transcript of Q2 2020 Earnings Call held on July 22, 2020. Exhibit (a)(5)(U) The following is an excerpt from the transcript of Thermo Fisher’s Q2 2020 earnings call held on July 22, 2020: Marc N. |
|
| July 22, 2020 |
EX-99.(A)(6) Exhibit 99(a)(6) – English Version – Mandatory Publication pursuant to Sec. 27 (3) in conjunction with Sec. 14 (3) sent. 1 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, WpÜG) and Voluntary publication pursuant to Sec. 18(2) in connection with Annex G of the Dutch Decree on Public Takeovers (Besluit Openbare Biedingen Wft) Supplemental J |
|
| July 22, 2020 |
EX-99.(A)(5)(S) Exhibit (a)(5)(S) QIAGEN announces publication of Supplemental Reasoned Position Statement for proposed acquisition by Thermo Fisher Venlo, the Netherlands, July 22, 2020 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the publication of its Supplemental Reasoned Position Statement in response to the amended Offer Document published by Thermo Fisher Scient |
|
| July 22, 2020 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) QIAGEN N.V. (Name of Subject Company) QIAGEN N.V. (Name of Persons Filing Statement) Ordinary shares, par value EUR 0.01 per share (Title of Class of Securities) N7248212 |
|
| July 22, 2020 |
EX-99.(A)(5)(T) Exhibit (a)(5)(T) English translation of the Notice of Publication as filed with the German Federal Gazette on July 22, 2020 QIAGEN N.V. Venlo, The Netherlands Shares of QIAGEN N.V.: ISIN NL0012169213 (WKN A2DKCH) Tendered Shares of QIAGEN N.V.: ISIN NL0014676538 (WKN A2P11F) Notice of Publication pursuant to Sec. 27 (3) sent. 1 and Sec. 14 (3) sent. 1 no. 2 alt. 2 of the German Se |
|
| July 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 14) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying sta |
|
| July 17, 2020 |
Amendment of the Offer, dated July 17, 2020. TABLE OF CONTENTS Exhibit (a)(1)(H) Mandatory publication pursuant to Sec. 34, 21 para. 1 sent. 1 no. 1, no. 3 and no. 4, para. 2 sent. 1 in conjunction with Sec. 14 para. 3 sent. 1 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, WpÜG) The Offer Document must be read in conjunction with this Amendment to the Offer. Unless otherwise specified in this p |
|
| July 17, 2020 |
Exhibit (a)(5)(S) Quebec B.V. Breda, The Netherlands Announcement pursuant to Sections 34, 21 para. 2 sentence 1 in conjunction with Section 14 para. 3 sentence 1 no. 2 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz — WpÜG) — Amendment of the Offer — NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION W |
|
| July 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 13) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying sta |
|
| July 16, 2020 |
Current Report of Foreign Issuer - 6-K 6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 16, 2020 |
AMENDMENT NO. 1 TO BUSINESS COMBINATION AGREEMENT EX-99.2 Exhibit 99.2 EXECUTION VERSION AMENDMENT NO. 1 TO BUSINESS COMBINATION AGREEMENT This AMENDMENT NO. 1 TO BUSINESS COMBINATION AGREEMENT (this “Amendment”), dated as of July 16, 2020, is by and between Thermo Fisher Scientific Inc., a Delaware corporation (“Buyer”), and QIAGEN N.V., a public limited liability company (naamloze vennootschap) incorporated under the laws of the Netherlands wit |
|
| July 16, 2020 |
Thermo Fisher Scientific and QIAGEN N.V. Agree on Amended Terms to Acquisition Agreement EX-99.1 Exhibit 99.1 News Thermo Fisher Media Contact Information: Karen Kirkwood Phone: 781-622-1306 E-mail: [email protected] Website: www.thermofisher.com Thermo Fisher Investor Contact Information: Ken Apicerno Phone: 781-622-1294 E-mail: [email protected] QIAGEN Media Contact Information: Dr. Thomas Theuringer Phone: +49 2103 29 11826 E-mail: thomas.theuringer@qiagen |
|
| July 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 12) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying sta |
|
| July 16, 2020 |
Press Release, dated July 16, 2020. Exhibit (a)(5)(R) News Thermo Fisher Media Contact Information: Karen Kirkwood Thermo Fisher Investor Contact Information: Ken Apicerno Phone: 781-622-1306 Phone: 781-622-1294 E-mail: karen. |
|
| July 16, 2020 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) QIAGEN N.V. (Name of Subject Company) QIAGEN N.V. (Name of Persons Filing Statement) Ordinary shares, par value EUR 0.01 per share (Title of Class of Securities) N7248212 |
|
| July 16, 2020 |
Exhibit (d)(8) AMENDMENT NO. 1 TO BUSINESS COMBINATION AGREEMENT This AMENDMENT NO. 1 TO BUSINESS COMBINATION AGREEMENT (this “Amendment”), dated as of July 16, 2020, is by and between Thermo Fisher Scientific Inc., a Delaware corporation (“Buyer”), and QIAGEN N.V., a public limited liability company (naamloze vennootschap) incorporated under the laws of the Netherlands with its corporate seat in |
|
| July 16, 2020 |
EX-99.(A)(5)(P) Exhibit (A)(5)(P) Key word(s): Increased Offer for QIAGEN Ad hoc Announcement according to Art. 17 Market Abuse Regulation Thermo Fisher to increase cash consideration and lower Acceptance Threshold in Offer for all shares of QIAGEN N.V. Venlo, The Netherlands, July 16, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) announces that Thermo |
|
| July 13, 2020 |
Exhibit (a)(5)(Q) Quebec B.V. Breda, The Netherlands Notification pursuant to Section 23 para. 1 sentence 1 no. 1 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz — WpÜG) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY OTHER JURISDICTION WHERE TO DO SO WOULD VIOLATE THE LAWS OF SUCH JURISDICTION. On May 18, 2020, |
|
| July 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 11) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying sta |
|
| July 13, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark wheth |
|
| July 9, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 Commission File Number 001-38332 QIAGEN N.V. (Translation of registrant’s name into English) Hulsterweg 82 5912 PL Venlo The Netherlands Indicate by check mark wheth |
|
| July 6, 2020 |
Exhibit (a)(5)(P) Quebec B.V. Breda, The Netherlands Notification pursuant to Section 23 para. 1 sentence 1 no. 1 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz — WpÜG) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY OTHER JURISDICTION WHERE TO DO SO WOULD VIOLATE THE LAWS OF SUCH JURISDICTION. On May 18, 2020, |
|
| July 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 10) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying sta |
|
| July 1, 2020 |
Exhibit (a)(5)(O) Quebec B.V. Breda, The Netherlands Announcement regarding the satisfaction of an offer condition NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY OTHER JURISDICTION WHERE TO DO SO WOULD VIOLATE THE LAWS OF SUCH JURISDICTION. On May 18, 2020, Quebec B.V., Breda, The Netherlands, (the “Bidder”) published the offer document (the “Offer Document |
|
| July 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 9) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying stat |
|
| June 29, 2020 |
Exhibit (a)(5)(N) Quebec B.V. Breda, The Netherlands Notification pursuant to Section 23 para. 1 sentence 1 no. 1 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz — WpÜG) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY OTHER JURISDICTION WHERE TO DO SO WOULD VIOLATE THE LAWS OF SUCH JURISDICTION. On May 18, 2020, |
|
| June 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 8) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying stat |
|
| June 22, 2020 |
Exhibit (a)(5)(M) Quebec B.V. Breda, The Netherlands Notification pursuant to Section 23 para. 1 sentence 1 no. 1 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz — WpÜG) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY OTHER JURISDICTION WHERE TO DO SO WOULD VIOLATE THE LAWS OF SUCH JURISDICTION. On May 18, 2020, |
|
| June 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 7) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying stat |
|
| June 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 6) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying stat |
|
| June 15, 2020 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) QIAGEN N.V. (Name of Subject Company) QIAGEN N.V. (Name of Persons Filing Statement) Ordinary shares, par value EUR 0.01 per share (Title of Class of Securities) N7248212 |
|
| June 15, 2020 |
Exhibit (a)(5)(L) Quebec B.V. Breda, The Netherlands Notification pursuant to Section 23 para. 1 sentence 1 no. 1 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz — WpÜG) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY OTHER JURISDICTION WHERE TO DO SO WOULD VIOLATE THE LAWS OF SUCH JURISDICTION. On May 18, 2020, |
|
| June 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying stat |
|
| June 8, 2020 |
EX-99.A5K 2 tm2016683-8ex99a5k.htm EXHIBIT 99.A5K Exhibit (a)(5)(K) Quebec B.V. Breda, The Netherlands Notification pursuant to Section 23 para. 1 sentence 1 no. 1 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz — WpÜG) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY OTHER JURISDICTION WHERE TO DO SO WOULD VIOLAT |
|
| June 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying stat |
|
| June 2, 2020 |
Exhibit (a)(5)(J) Quebec B.V. Breda, The Netherlands Notification pursuant to Section 23 para. 1 sentence 1 no. 1 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz — WpÜG) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY OTHER JURISDICTION WHERE TO DO SO WOULD VIOLATE THE LAWS OF SUCH JURISDICTION. On May 18, 2020, |
|
| May 26, 2020 |
Exhibit (a)(5)(I) Quebec B.V. Breda, The Netherlands Notification pursuant to Section 23 para. 1 sentence 1 no. 1 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz — WpÜG) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY OTHER JURISDICTION WHERE TO DO SO WOULD VIOLATE THE LAWS OF SUCH JURISDICTION. On May 18, 2020, |
|
| May 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying stat |
|
| May 18, 2020 |
Supplementary Agreement to the service agreement of December 21th, 2017 EX-99.(e)(15) Exhibit (e)(15) THIS AGREEMENT is entered into between the parties on December 21st, 2017. PARTIES (1) QIAGEN MANCHESTER LIMITED a company incorporated and registered in England and Wales with company number 04160032 and whose registered office is at Skelton House, Lloyd Street North, Manchester, M15 6SH (the “Company”); and (2) Jonathan Sheldon, [Address] (the “Executive”). AGREED T |
|
| May 18, 2020 |
EX-99.(e)(20) Exhibit (e)(20) EXECUTION VERSION March 2, 2020 Re: Treatment of Equity Awards Granted On or After January 1, 2020 Dear Barthold: In connection with the transactions contemplated by the Business Combination Agreement to be entered into between THERMO FISHER SCIENTIFIC INC. (“Triton”) and QIAGEN N.V. (“Quebec”) (the “BCA”) and in consideration for the terms of your continued employmen |
|
| May 18, 2020 |
EX-99.(e)(17) Exhibit (e)(17) EMPLOYMENT CONTRACT THE UNDERSIGNED: 1. Q Biotechnology C.V., a limited partnership, having its registered office at Hulsterweg 82, (5912 PL) Venlo, The Netherlands, duly represented by on behalf of Life Biotech Partners B.V., hereinafter to be referred to as the ‘Employer’; And 2. Jean-Pascal Viola residing at [Address], hereinafter to be referred to as the ‘Employee |
|
| May 18, 2020 |
Letter Agreement between Jonathan Sheldon and Thermo Fisher Scientific Inc. dated March 2, 2020.* Exhibit (d)(5) March 2, 2020 Re: Treatment of Equity Awards Granted On or After January 1, 2020 Dear Jonathan: In connection with the transactions contemplated by the Business Combination Agreement to be entered into between THERMO FISHER SCIENTIFIC INC. |
|
| May 18, 2020 |
EX-99.(e)(10) Exhibit (e)(10) EMPLOYMENT AGREEMENT THE UNDERSIGNED: 1. The public limited liability company QIAGEN N.V., having its registered office at Spoorstraat 42 — 52, NL - Venlo, in this matter duly represented by Mr. Peer M. Schatz, hereinafter to be referred to as the `Company’; and 2. Roland Sackers, residing at [Address], hereinafter to be referred to as the `Deputy Managing Director’; |
|
| May 18, 2020 |
Notice of Stock Option Grant under The Company’s Amended and Restated 2005 Stock Plan EX-99.(e)(4)(b) Exhibit (e)(4)(B) Notice of Stock Option Grant under The Company’s Amended and Restated 2005 Stock Plan %%FIRSTNAME%% %%LASTNAME%-% %%ADDRESSLINE1%-% %%ADDRESSLINE2%-% %%CITY%-%, %%ZIP%-% %%COUNTRY%-% Dear %%FIRSTNAME%-%: I am very pleased to notify you of a new grant of stock options. Effective %%OPTIONDATE%-% (the “Date of Grant”), you have been granted a Non-qualified Option (th |
|
| May 18, 2020 |
SC 14D9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 QIAGEN N.V. (Name of Subject Company) QIAGEN N.V. (Name of Persons Filing Statement) Ordinary shares, par value EUR 0.01 per share (Title of Class of Securities) N72482123 (CUSIP Number of C |
|
| May 18, 2020 |
EX-99.(e)(9) Exhibit (e)(9) December 4, 2019 Thierry Bernard [Address] Re: Interim CEO Role Dear Thierry, On behalf of QIAGEN LLC (the “Company”), we are pleased to confirm your new role as Interim CEO of the QIAGEN group of companies. This role is distinct from your existing role as Senior Vice President, Head of Business Area Molecular Diagnostics, which is the subject of your employment agreeme |
|
| May 18, 2020 |
Letter Agreement between Thomas Schweins and Thermo Fisher Scientific Inc. dated March 2, 2020.* Exhibit (d)(4) March 2, 2020 Re: Treatment of Equity Awards Granted On or After January 1, 2020 Dear Thomas: In connection with the transactions contemplated by the Business Combination Agreement to be entered into between THERMO FISHER SCIENTIFIC INC. |
|
| May 18, 2020 |
Letter Agreement between Barthold Piening and Thermo Fisher Scientific Inc. dated March 2, 2020.* Exhibit (d)(3) March 2, 2020 Re: Treatment of Equity Awards Granted On or After January 1, 2020 Dear Barthold: In connection with the transactions contemplated by the Business Combination Agreement to be entered into between THERMO FISHER SCIENTIFIC INC. |
|
| May 18, 2020 |
Important update on Thermo Fisher acquisition process EX-99.(a)(5)(o) Exhibit (a)(5)(o) Important update on Thermo Fisher acquisition process Dear QIAGENers: This is an important update on the process for Thermo Fisher to acquire QIAGEN. Our key message for you today is that we have reached the next steps in this transaction, which is according to current planning expected to be completed in the first half of 2021. Press releases were issued today by |
|
| May 18, 2020 |
Text of Summary Advertisement as published in The Wall Street Journal on May 18, 2020.* Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell any QIAGEN Shares (as defined below), and statements made herein are subject in their entirety to the provisions of the Offer (as defined below). |
|
| May 18, 2020 |
EX-99.(e)(14) Exhibit (e)(14) Employment Contract Page 2 of the Employment Contract of Dr. Thomas Schweins Employment Contract Between QIAGEN GmbH QIAGEN Str. 1 40724 Hilden - hereinafter referred to as QIAGEN - and Dr. Thomas Schweins [Address] - hereinafter referred to as Employee - Preamble With effect from 1 January 2006, this employment contract replaces the employment contract concluded on 1 |
|
| May 18, 2020 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.* Exhibit (a)(1)(D) OFFER TO PURCHASE FOR CASH All Shares of QIAGEN N.V. at EUR 39.00 per Share Pursuant to the Offer Document published May 18, 2020 by QUEBEC B.V. a wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. THE ACCEPTANCE PERIOD COMMENCED ON MAY 18, 2020 AND WILL EXPIRE AT 6:00 P.M. NEW YORK LOCAL TIME, ON JULY 27, 2020, UNLESS THE ACCEPTANCE PERIOD IS EXTENDED OR THE OFFER IS EARLI |
|
| May 18, 2020 |
Offer Document, dated May 18, 2020.* TABLE OF CONTENTS Exhibit (a)(1)(A) Mandatory publication pursuant to Sec. 34, 14 paras. 2 and 3 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, WpÜG) Shareholders of QIAGEN N.V., in particular those who have their place of residence, seat or place of habitual abode in the United States of America or otherwise outside the Federal Republic of Germany, |
|
| May 18, 2020 |
EX-99.(a)(5)(n) Exhibit (a)(5)(n) English translation of the Notice of Publication as filed with the German Federal Gazette on May 18, 2020 QIAGEN N.V. Venlo, The Netherlands Shares of QIAGEN N.V.: ISIN NL0012169213 (WKN A2DKCH) Tendered Shares of QIAGEN N.V.: ISIN NL0014676538 (WKN A2P11F) Notice of Publication pursuant to Sec. 27 (3) sent. 1 and Sec. 14 (3) sent. 1 no. 2 alt. 2 of the German Sec |
|
| May 18, 2020 |
Non-Tender Agreement between QIAGEN N.V. and Quebec B.V., dated April 27, 2020.* Exhibit (d)(7) EXECUTION COPY Dated April 27, 2020 QIAGEN N.V. Quebec B.V. NON-TENDER AGREEMENT THIS AGREEMENT IS MADE Between (1) QIAGEN N.V., a limited liability company (naamloze vennootschap) organized under the laws of The Netherlands, having its corporate seat in Venlo, The Netherlands and registered with the Dutch trade register under number 12036979 (hereinafter the “Company” or “QIAGEN”), |
|
| May 18, 2020 |
EX-99.(e)(12) Exhibit (e)(12) [01.12.2006] Roland Sackers [Address] Re: Employment Agreement Dear Roland: This letter is to confirm our understanding with respect to your employment in the United States by QIAGEN N.V., QIAGEN Deutschland Holding GmbH, and QIAGEN North American Holdings, Inc. (collectively, the “Company”) for the period of calendar years 2006, 2007 and 2008. In consideration of the |
|
| May 18, 2020 |
Confidentiality and Non-Disclosure Agreement EX-99.(e)(25) Exhibit (e)(25) Confidentiality and Non-Disclosure Agreement For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound hereby, each of QIAGEN N.V. (collectively with its affiliates and subsidiaries, the “Company”) and the undersigned party (the “Undersigned”, and together with the Company, the “Parties’’ and ea |
